INTRODUCTION {#S1}
============

The survival of any species is contingent upon the ability to physiologically and behaviorally adapt to a changing nutritional environment. In mammals, this homeostasis is largely mediated by nutritional hormones, which coordinate changes in feeding behavior, energy expenditure, substrate metabolism, and growth in response to fluctuations in nutrient availability. Essential amino acids are required for optimal health and performance, and animals sense and respond to reductions in the consumption of dietary protein ([@R20]; [@R41]). In mice, this metabolic response includes increased energy expenditure, reduced growth, and enhanced insulin sensitivity and glucose homeostasis ([@R9]; [@R14]; [@R19]; [@R27]; [@R36]). Protein restriction also alters feeding behavior to increase protein intake by promoting the overconsumption of a single low-protein diet (protein leverage) or altering food choice, such that higher protein foods are preferred ([@R7]; [@R16]; [@R21]; [@R43]; [@R54]; [@R60]).

Although the mechanisms underlying adaptive responses to protein restriction are not well defined, our laboratory and that of others have demonstrated that the metabolic hormone fibroblast growth factor 21 (FGF21) is essential for this metabolic response ([@R20], [@R19]; [@R27], [@R29]; [@R36]). FGF21 is a member of a small subfamily of "endocrine fibroblast growth factors (FGFs)," being produced primarily by the liver and signaling at distant sites via the FGF receptor 1c (FGFR1c) and the co-receptor bKlotho (*Klb*) ([@R33]; [@R38]; [@R44]; [@R45]). Pharmacological FGF21 treatment reduces body weight, increases energy expenditure, improves insulin sensitivity, and improves lipid metabolism in rodents, non-human primates, and humans ([@R8]; [@R15]; [@R24]; [@R25]; [@R48]; [@R63]), and this effect is argued to be driven by direct effects on both adipose tissue and the brain ([@R4]). FGF21 has also been linked to macronutrient preference because pharmacological FGF21 treatment reduces the consumption of sweet substances and alcohol ([@R56]; [@R62]; [@R65]).

Because FGF21 has a critical role in the response to protein restriction, we sought to identify the primary site mediating that FGF21-dependent effect, hypothesizing that FGF21 likely acted directly in the CNS to coordinate changes in food intake and energy expenditure. Because protein restriction also produces a macronutrient-specific appetite for protein, we hypothesized that FGF21 mediated that change in macronutrient preference. We demonstrate that FGF21 signaling within the brain is the fundamental mediator of physiological changes in both metabolism and macronutrient preference during protein restriction. In the absence of brain FGF21 signaling, mice are unable to mount a metabolic response to protein restriction, and central FGF21 mediates adaptive changes in macronutrient preference during protein restriction. Collectively, these data not only demonstrate that this liver-to-brain FGF21 signal mechanistically underpins a fundamental aspect of biology, but they also provide a conceptual framework that cohesively defines the physiological relevance of FGF21.

RESULTS {#S2}
=======

FGF21 Signaling in Brain but not Adipose Tissue Mediates Low-Protein-Induced Metabolic Responses in Lean Mice {#S3}
-------------------------------------------------------------------------------------------------------------

*Fgf21*-knockout (KO) mice do not exhibit a metabolic response to a low-protein diet ([@R19]; [@R27], [@R29]). To test whether the FGF21-dependent effect is mediated by direct signaling in the brain, we used Camk2a-Cre, which has previously been used to delete *Klb* from the brain ([@R5]; [@R46]) and which primarily targets neurons within the forebrain ([@R6]). *Klb*^*Camk2a*^ mice and control littermates (*Klb*^*lox/lox*^) were placed *ad libitum* on isocalorically normal protein (Con) or low-protein (LP) diets for 7 weeks. LP diet increased circulating FGF21 levels ([Figure 1A](#F1){ref-type="fig"}) and hepatic *Fgf21* expression ([Figure 1B](#F1){ref-type="fig"}) in both *Klb*^*lox/lox*^ and *Klb*^*Camk2a*^ mice. *Klb* mRNA expression was selectively reduced within the brain of *Klb*^*Camk2a*^ mice ([Figure 1C](#F1){ref-type="fig"}). LP diet also increased liver markers of amino acid restriction (*Phgdh* and *Asns*) within both genotypes ([Figure 1D](#F1){ref-type="fig"}).

Although the LP diet increased food intake in *Klb*^*lox/lox*^ mice, the effect was lost in *Klb*^*Camk2a*^ mice ([Figure 1E](#F1){ref-type="fig"}). Furthermore, the reduction in body-weight gain observed in LP-fed *Klb*^*lox/lox*^ mice was also lost in *Klb*^*Camk2a*^ mice ([Figures 1F](#F1){ref-type="fig"} and [1G](#F1){ref-type="fig"}). Finally, LP-induced changes in fat and lean gain were not observed in *Klb*^*Camk2a*^ mice ([Figures 1H](#F1){ref-type="fig"} and [1I](#F1){ref-type="fig"}). The observation of increased food intake but reduced body weight in *Klb*^*lox/lox*^ mice on the LP diet was consistent with increased energy expenditure, and direct measures of the rate of oxygen consumption (VO~2~) and energy expenditure (EE) confirmed an LP-induced increase only in *Klb*^*lox/lox*^ mice ([Figures 1J](#F1){ref-type="fig"} and [1K](#F1){ref-type="fig"}). The LP diet also increased *Ucp1* mRNA expression within inguinal white adipose tissue (iWAT) of *Klb*^*lox/lox*^, but not *Klb*^*Camk2a*^, mice ([Figure 1L](#F1){ref-type="fig"}). Taken together, these data demonstrate that CNS FGF21 signaling is required for lean mice to metabolically respond to dietary protein restriction.

Because adipose tissue expresses Klb and directly responds to FGF21, adipose-specific *Klb* KO mice (Klb^Adipo^) and control littermates (*Klb*^*lox/lox*^) were placed on Con or LP diets for 6 weeks *ad libitum.* The LP diet increased circulating FGF21 and liver *Fgf21* mRNA in both *Klb*^*lox/lox*^ and Klb^Adipo^ mice ([Figure S1A](#SD1){ref-type="supplementary-material"} and [1B](#SD1){ref-type="supplementary-material"}), whereas Klb mRNA was substantially reduced within the adipose tissue of Klb^Adipo^ mice ([Figure S1C](#SD1){ref-type="supplementary-material"}). Food intake was increased in both LP-fed *Klb*^*lox/lox*^ and Klb^Adipo^ mice ([Figure S1D](#SD1){ref-type="supplementary-material"}). The LP fed Klb^Adipo^ and *Klb*^*lox/lox*^ mice also exhibited similar reductions in body weight, fat, and lean gain ([Figures S1E](#SD1){ref-type="supplementary-material"}--[S1H](#SD1){ref-type="supplementary-material"}). Consistent with previously observed effects on EE, the LP diet increased iWAT *Ucp1* mRNA expression in both LP groups, and both groups exhibited increased food intake but reduced body-weight gain ([Figure S1I](#SD1){ref-type="supplementary-material"}). Collectively, these data suggest that FGF21 signaling directly in adipose tissue is not necessary for changes in body weight and food intake in response to protein restriction.

Comparison of the Metabolic Effects of Protein Restriction versus Dietary Restriction in Obese Mice {#S4}
---------------------------------------------------------------------------------------------------

Dietary protein restriction improves glucose homeostasis in settings of diet induced obesity ([@R9]; [@R14]; [@R30]; [@R36], [@R37]; [@R57]) and represents an alternative nutritional strategy to general dietary (calorie) restriction. To directly compare the metabolic effect of protein restriction and dietary (food) restriction in obese mice, wild-type mice were fed either a 60% high-fat diet (HFD) *ad libitum* (HFCon), a 60% HFD that was low in protein (HFLP), or a diet-restriction group (HFDR), in which mice consumed HFCon but were food restricted to match body weight to the HFLP group. HFLP reduced body weight and fat gain despite *ad libitum* feeding, and that weight loss was matched by experimentally reducing food intake by 25% in the HFDR group ([Figures S2A](#SD1){ref-type="supplementary-material"} and [S2B](#SD1){ref-type="supplementary-material"}; p \< 0.05). Thus,Ȉboth energy and protein intake were reduced (Ȉ25%) in HFDR mice, whereas HFLP increased energy intake but reduced protein intake ([Figures 2C](#F2){ref-type="fig"} and [2D](#F2){ref-type="fig"}; p \< 0.05). Fasting insulin levels trended lower in the HFLP, but not the HFDR, group ([Figure S3G](#SD1){ref-type="supplementary-material"} and [S3H](#SD1){ref-type="supplementary-material"}), and there was no change in the insulin positive area within pancreatic islets (data not shown). Glucose tolerance at week 4 was improved in both HFLP and HFDR mice ([Figures S2E](#SD1){ref-type="supplementary-material"} and [S2F](#SD1){ref-type="supplementary-material"}; p \< 0.05). Liver lipogenic genes (*Fasn*, *Scd-1*, *Srebp-1*) were significantly increased by HFDR but unaffected or reduced by HFLP ([Figure S2K](#SD1){ref-type="supplementary-material"}; p \< 0.05). Liver markers of amino acid restriction (*Asns* and *Phgdh)* were increased in HFLP, but unchanged in HFDR, mice ([Figure S2L](#SD1){ref-type="supplementary-material"}; p \< 0.05). Consistent with alternative effects on EE, levels of *Ucp1* within iWAT were robustly increased by HFLP but unaffected by HFDR ([Figure S2M](#SD1){ref-type="supplementary-material"}; p \< 0.05). Finally, circulating FGF21 levels and liver Fgf21 mRNA expression were robustly increased by HFLP but not HFDR ([Figures S2I](#SD1){ref-type="supplementary-material"} and [S2J](#SD1){ref-type="supplementary-material"}; p \< 0.01). Taken together, these data demonstrate that protein restriction improves metabolic endpoints in the context of diet-induced obesity but does so by activating pathways that are different from classic dietary (calorie) restriction, most notably the induction of FGF21.

Protein Restriction Protects against HFD-Induced Obesity and Glucose Intolerance via FGF21 Action in the Brain {#S5}
--------------------------------------------------------------------------------------------------------------

We next tested whether FGF21 is required for the abovedescribed protective effects of protein restriction in the context of diet-induced obesity. Wild-type (WT) and *Fgf21*-KO mice were placed on HFCon or HFLP for 6 weeks. HFLP increased serum FGF21 levels in LP-fed WT mice, whereas FGF21 levels were undetectable in *Fgf21*-KO mice ([Figure 2A](#F2){ref-type="fig"}; p \< 0.001). WT mice on the HFCon diet exhibited a steady increase in body weight that was reduced by HFLP, with HFLP also reducing fat gain and percentage of body fat ([Figures 2B](#F2){ref-type="fig"} and [2D](#F2){ref-type="fig"}--[2F](#F2){ref-type="fig"}; p \< 0.05). Contrastingly, HFLP had no effect on weight or fat gain in *Fgf21*-KO mice ([Figures 2C](#F2){ref-type="fig"} and [2D](#F2){ref-type="fig"}--[2F](#F2){ref-type="fig"}; p \< 0.05). The weight-reducing effect of the HFLP diet cannot be explained by changes in food intake because HFLP increased food intake in WT mice but not *Fgf21*-KO mice ([Figure 2G](#F2){ref-type="fig"}; p \< 0.05). Consistent with increased EE, HFLP increased iWAT *Ucp1* mRNA expression in WT mice but not *Fgf21*-KO mice ([Figure 2H](#F2){ref-type="fig"}; p \< 0.001). Finally, the HFLP diet improved glucose tolerance ([Figures 2I](#F2){ref-type="fig"} and [2K](#F2){ref-type="fig"}; p \< 0.01) and lowered insulin levels in WT mice ([Figure 2L](#F2){ref-type="fig"}; p \< 0.01), and these effects were also lost in *Fgf21*-KO mice ([Figures 2J](#F2){ref-type="fig"}--[2L](#F2){ref-type="fig"}).

Because dietary protein restriction protects against HFDinduced obesity and glucose intolerance via an FGF21-dependent mechanism, we next tested whether that protective effect also required FGF21 signaling in the brain. Brain-specific *Klb* KO mice (*Klb*^*Camk2a*^) and control littermates (*Klb*^*lox/lo*x^) were placed on HFCon or HFLP diets, the same as that above, for 10 weeks. Consistent with previous data, HFLP increased circulating FGF21 levels ([Figure 3A](#F3){ref-type="fig"}; p \< 0.001) and hepatic *Fgf21* mRNA expression ([Figure 3B](#F3){ref-type="fig"}; p \< 0.001) in both *Klb*^*lox/lox*^ and *Klb*^*Camk2a*^ mice. In *Klb*^*lox/lox*^ mice, HFLP increased food intake ([Figure 3C](#F3){ref-type="fig"}; p \< 0.05), increased iWAT *Ucp1* mRNA expression ([Figure 3D](#F3){ref-type="fig"}; p \< 0.001), reduced body weight and fat and lean gain ([Figures 3E](#F3){ref-type="fig"}--[3H](#F3){ref-type="fig"}; p \< 0.05). All of these effects were lost in *Klb*^*Camk2a*^ mice. As in WT mice, HFLP improved both glucose tolerance and insulin sensitivity in *Klb*^*lox/lox*^ mice ([Figures 3I](#F3){ref-type="fig"} and [3J](#F3){ref-type="fig"}; p \< 0.05) and also reduced fasting blood glucose and insulin levels in *Klb*^*lox/lox*^ mice ([Figure 3K](#F3){ref-type="fig"}; p \< 0.001 and 3L; p \< 0.001). These effects of HFLP on glucose homeostasis were lost in *Klb*^*Camk2a*^ mice. There were no dietary effects on circulating adiponectin levels in either *Klb*^*lox/lox*^ or *Klb*^*Camk2a*^ mice ([Figure 3M](#F3){ref-type="fig"}). Collectively, the data in [Figures 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}, and [S2](#SD1){ref-type="supplementary-material"} use three separate mouse studies and two independent mouse genetic models to demonstrate that dietary protein restriction improves metabolic outcomes in diet-induced obese mice and that these beneficial effects are fully dependent on FGF21 and its signaling via Klb within the brain.

FGF21 Acts in the Brain to Increase Protein Intake {#S6}
--------------------------------------------------

In addition to inducing metabolic adaptations, protein restriction also induces a shift in macronutrient preference toward increased protein intake ([@R7]; [@R16]; [@R21]; [@R43]; [@R54]; [@R60]). To test whether FGF21 mediates that shift in macronutrient preference, we first tested the effects of FGF21 on protein selection in mice that were simultaneously offered two isocaloric diets that varied in their protein:carbohydrate ratio (see [Table S1](#SD1){ref-type="supplementary-material"} for diet compositions). Mice were given 1 week to adapt to those diets, and then FGF21 (1 mg) was injected into the lateral ventricle for 3 consecutive days, approximately 3 h before lights were turned off. The first diet comparison was mice choosing between 5% and 35% casein diets ([Figure 4](#F4){ref-type="fig"}). Intracerebroventricular (ICV) FGF21 acutely reduced the consumption of the lower (5%) protein diet ([Figure 4A](#F4){ref-type="fig"}; p \< 0.05) and produced a slightly delayed and more prolonged increase in consumption of the higher (35%) protein choice ([Figure 4B](#F4){ref-type="fig"}; p \< 0.05). Total intake was not consistently affected by FGF21 injection ([Figure 4C](#F4){ref-type="fig"}). Expressing these data as a preference ratio for the 35% diet (intake of 35% divided by total intake) indicates that FGF21 significantly increased preference for 35% by day 2 after the injection ([Figure 4D](#F4){ref-type="fig"}; p \< 0.05), with the preference ratio returning to normal by day 6 (3 days after the injection). Averaging consumption across days 1--5 revealed that FGF21 decreased consumption of 5%, increased consumption of 35% and preference for 35%, and increased total protein intake but had no effect on total food intake ([Figures 4E](#F4){ref-type="fig"}--[4G](#F4){ref-type="fig"}; p \< 0.05). This FGF21-induced increase in protein intake was replicated in additional dietary combinations, including 10% versus 40% casein diets and 5% versus 60% casein diets ([Figure S3](#SD1){ref-type="supplementary-material"}). In each case, ICV FGF21 increased preference for the high-protein choice and increased total protein intake but did not increase total food intake.

We then used the geometric framework ([@R50]; [@R54]; [@R60]) to directly compare cumulative carbohydrate versus protein intake over time within each individual experiment ([Figures 4H](#F4){ref-type="fig"}--[4J](#F4){ref-type="fig"}). In all three experiments, ICV FGF21 significantly increased cumulative protein intake (p \< 0.05), demonstrated by a rightward shift in the FGF21 group (highlighted with a vertical red line). Contrastingly, there was no consistent change along the horizontal carbohydrate axis, although carbohydrate intake was slightly reduced by FGF21 injection in the 5% versus 60% group. These data collectively demonstrate that FGF21 acts in the brain to increase protein intake without significantly altering total food (energy) intake or carbohydrate intake.

Protein-Restricted Mice Exhibit a Specific Appetite for Protein {#S7}
---------------------------------------------------------------

The above data indicate that FGF21 increases protein intake. To further explore protein and carbohydrate consumption, we adopted a protocol previously described by [@R43], in which carbohydrate (maltodextrin) and protein (casein) are offered in liquid form to allow independent consumption and choice between these purified macronutrients. In that work, the protein-restricted rats drank significantly more casein than the control rats, and we, therefore, first sought to reproduce this effect in mice. WT mice were fed either control or LP for 1 week and were then offered 4% casein or 4% maltodextrin solutions for 3 consecutive days. LP mice exhibited a robust and sustained increase in casein intake on all three days of exposure ([Figure S4A](#SD1){ref-type="supplementary-material"}; p \< 0.05), but there was no significant effect on maltodextrin intake ([Figure S4B](#SD1){ref-type="supplementary-material"}). Casein and maltodextrin were then offered simultaneously in a two-choice paradigm for 3 consecutive days. Although control-fed mice preferred maltodextrin, LP mice exhibited a significant decrease in maltodextrin intake, a significant increase casein intake, and a strong increase in preference for casein ([Figures S4C](#SD1){ref-type="supplementary-material"} and [S4D](#SD1){ref-type="supplementary-material"}). These data indicate the protein-restricted mice specifically increased casein, but not maltodextrin, consumption in a single-choice paradigm and shifted away from maltodextrin and toward casein in a twochoice paradigm.

CNS FGF21 Signaling Is Required for Physiological Shifts in Protein Preference {#S8}
------------------------------------------------------------------------------

To determine whether FGF21 is also required for LP-induced shifts in macronutrient preference, we repeated the above experiments in additional groups of WT and *Fgf21*-KO mice. In single-choice, WT LP-fed (WTLP) mice significantly increased casein consumption ([Figure 5A](#F5){ref-type="fig"}; p \< 0.05) and tended to reduce maltodextrin intake ([Figure 5B](#F5){ref-type="fig"}; p = 0.06). *Fgf21*-KO mice on LP exhibited no change in consumption of either macronutrient ([Figures 5A](#F5){ref-type="fig"} and [5B](#F5){ref-type="fig"}). When both macronutrients were offered simultaneously (two-choice), WTLP mice reduced maltodextrin intake and increased casein intake ([Figure 5C](#F5){ref-type="fig"}; p \< 0.05), which translated into a strong and significant shift in casein preference ([Figure 5E](#F5){ref-type="fig"}; p \< 0.05). As above, *Fgf21*-KO mice were completely resistant to these effects of LP diet, exhibiting no change in maltodextrin or casein intake or casein preference in the twochoice setting ([Figures 5D](#F5){ref-type="fig"} and [5E](#F5){ref-type="fig"}). To test whether CNS FGF21 signaling mediated that effect, we repeated the twochoice paradigm in brain-specific Klb KOs (*Klb*^*Camk2a*^) and their littermate controls (*Klb*^*lox/lox*^). The LP diet significantly reduced maltodextrin intake and increased casein intake in *Klb*^*lox/lox*^ controls ([Figure 5F](#F5){ref-type="fig"}; p \< 0.05), resulting in a strong increase in casein preference ([Figure 5H](#F5){ref-type="fig"}; p \< 0.05). These effects were completely lost in *Klb*^*Camk2a*^ mice ([Figures 5G](#F5){ref-type="fig"} and [5H](#F5){ref-type="fig"}), replicating the phenotype of *Fgf21*-KO mice. These data clearly indicate that mice adaptively shift macronutrient preference in response to protein restriction and that FGF21 signaling in the brain mediates the response.

To more closely analyze the timing of the macronutrient preference, we repeated the two-choice paradigm within automated feeding chambers, which allowed continuous assessment of casein and maltodextrin intake over time. WT and *Fgf21*-KO mice were placed on control and LP diets for 1 week and then provided with maltodextrin and casein solutions for 42 h. Importantly, this design allowed the continuous assessment of macronutrient choice in mice that were naive to the solutions, in contrast to the previous studies in which mice had experience with the solutions before the two-choice study. In this scenario, WTLP mice rapidly and persistently increased casein intake ([Figure 6A](#F6){ref-type="fig"}) and tended to reduce maltodextrin intake ([Figure 6B](#F6){ref-type="fig"}) but did not change total intake ([Figure 6C](#F6){ref-type="fig"}) and, thus, exhibited a strong and persistent shift in casein preference ([Figure 6D](#F6){ref-type="fig"}). These effects were lost in *Fgf21*-KO mice. We then more narrowly analyzed the first 5 h of liquid consumption in WTCON and WTLP mice. Because the above data were generated in two replicates, which differed slightly (by 45 min) in the time the fluids were offered relative to lights being turned off, we focused on the first replicate (n = 3), in which fluids were presented simultaneously. In WTLP mice, increased casein consumption was visually apparent early during exposure, diverging statistically (p \<0.05) at Ȉ150 min after initial presentation. Maltodextrin intake diverged slightly later (180 min), but there was no change in total intake. These data suggest that casein preference manifests relatively rapidly in protein-restricted mice that are naive to the solutions; however, these data are insufficient to distinguish between an innate, unlearned preference verses a preference that is learned through the postingestive consequences.

CNS FGF21 Signaling Increases Protein Intake in ChowFed Mice {#S9}
------------------------------------------------------------

Because CNS FGF21 signaling is necessary for adaptive changes in casein preference, we finally tested whether stimulation of central FGF21 signaling would mimic the effects of protein restriction and cause chow-fed mice to exhibit a protein preference, even though they are not protein restricted. WT mice on chow were offered both casein and maltodextrin (two-choice) for 3 days, with a single ICV FGF21 injection on the second day (day 1). FGF21 significantly increased casein intake ([Figure 7A](#F7){ref-type="fig"}; p \< 0.05) without significantly altering maltodextrin ([Figure 7B](#F7){ref-type="fig"}) or total intake ([Figure 7C](#F7){ref-type="fig"}), resulting in a significant increase in preference for casein ([Figure 7D](#F7){ref-type="fig"}; p \< 0.05). We then repeated the study in *Klb*^*Camk2a*^ and *Klb*^*lox/lox*^ littermates. As before, ICV FGF21 injection increased casein intake ([Figure 7E](#F7){ref-type="fig"}; p \< 0.05) and preference for casein ([Figure 7H](#F7){ref-type="fig"}; p \< 0.05) in *Klb*^*lox/lox*^ mice but had no effect in *Klb*^*Camk2a*^ mice. These data demonstrate that FGF21 signaling within the brain shifts macronutrient preference toward protein, and that this effect requires neuronal Klb signaling.

DISCUSSION {#S10}
==========

Adapting to reductions in nutrient availability is an essential characteristic of life. Mammals adaptively respond to reductions in nutrients, such as energy, water, or salt, and these adaptive responses are generally mediated by endocrine hormones, which coordinate both metabolic and behavioral adaptations. Protein is also an essential nutrient, and it has long been known that dietary protein restriction triggers changes in food intake, energy expenditure, substrate metabolism, growth, and other metabolic endpoints ([@R21]; [@R28]; [@R41]; [@R42]; [@R51]; [@R57], [@R58]; [@R67], [@R68]). However, the mechanistic basis for this response has lagged behind other nutrients, despite the intense focus on protein intake and protein supplementation within popular culture and despite the potential power of tapping into this mechanism.

Our laboratory recently demonstrated that the metabolic hormone FGF21 is essential for coordinating the metabolic response to protein restriction in lean mice ([@R19]; [@R27], [@R29]). Here, we define the mechanism through which FGF21 mediates those effects. First, we use tissue-specific deletion of the FGF21 co-receptor Klb to demonstrate that FGF21 signaling within the brain, but not within adipose tissue, is required for the metabolic response to protein restriction. Prior work using either pharmacological FGF21 injection or transgenic overexpression has demonstrated that FGF21 acts in the CNS to reduce body weight, improve glucose homeostasis, and stimulate adipose tissue thermogenesis ([@R5]; [@R11]; [@R31]; [@R35]; [@R47]; [@R53]). Here, we used the physiological model of dietary protein restriction to show that selective deletion of *Klb* from the CNS fully blocks the effects of protein restriction on food intake, energy expenditure, body weight gain, and iWAT *Ucp1* mRNA expression. In their inability to respond to protein restriction, the *Klb*^*Camk2a*^ mice, therefore, fully recapitulate the phenotype of whole-body *Fgf21*-KO mice, and this replication across two independent mouse lines argues against any non-specific effect of either genetic line.

Contrastingly, deletion of Klb from adipose tissue failed to block changes in food intake, growth, or iWAT *Ucp1* mRNA expression, suggesting that FGF21 signaling in adipose tissue is not required for metabolic responses to protein restriction. FGF21 was first noted for its ability to promote glucose uptake in adipocytes ([@R26]), and multiple studies have since suggested that FGF21 influences metabolism, at least in part, via direct effects on adipose tissue ([@R1]; [@R3]; [@R26]). However, recent studies suggested that *Klb* in adipose tissue is only required for the acute, but not chronic, effects of pharmacological FGF21 treatment ([@R3]). Our data provide strong evidence that the brain is the primary site of FGF21 action in settings of physiological FGF21 induction and, therefore, that this liver-to-brain FGF21 signal is the mechanism through which lean mice sense and respond to protein restriction.

Dietary protein restriction also improves metabolic endpoints in settings of diet-induced obesity, increasing energy expenditure, reducing body weight gain, and improving glucose homeostasis ([@R9]; [@R14]; [@R30]; [@R36], [@R37]; [@R57]). In our work initially establishing this high-fat, low-protein model, we compared the effects of protein restriction (HFLP) to an equivalent weight loss induced by typical dietary/caloric restriction (HFDR). Although both interventions produced weight loss and improved glucose homeostasis, there were notable differences in the mechanisms induced. First, HFLP "spontaneously" reduced weight gain and improved glucose tolerance and fasting insulin levels, whereas HFDR required an experimentally imposed 25% food restriction to achieve similar effects. Second, these interventions exerted opposing effects on energy intake and EE because HFLP increased energy intake and EE and browned inguinal white fat ([@R19]), whereas HFDR reduced energy intake and likely EE ([@R17]; [@R34]). The increased EE in protein-restricted mice is dependent on uncoupling protein 1 (UCP1) ([@R19]; [@R66]) and is thought to be an adaptive, metabolic response, which allows an animal to overconsume nutritionally imbalanced diets, thus increasing intake of the missing nutrient (protein) and disposing of the excess energy via increased EE ([@R13]; [@R50]). Third, hepatic expression of genes associated with amino acid biosynthesis and lipogenesis were markedly different between the groups. Finally and importantly, only HFLP produced a significant change in liver *Fgf21* mRNA expression and circulating FGF21 protein. These data highlight the differences between protein restriction and dietary restriction, particularly the selective increase of FGF21 ([@R27]; [@R59]; [@R64]; [@R69]).

Brain FGF21 signaling is critical for metabolic effects of protein restriction in lean mice, and protein restriction improves metabolic health in settings of diet-induced obesity. We, therefore, tested whether whole-body FGF21 deletion or brain-specific Klb deletion influenced LP-induced effects in obese mice. Consistent with the above data, HFLP exerted potent metabolic effects in both WT and *Klb*^*lox/lox*^ mice, including reduced body weight gain, despite increased food intake, increased iWAT *Ucp1* mRNA expression, improved glucose tolerance, and lower insulin levels. These effects were completely lost in *Fgf21*-KO mice and were also lost in mice lacking Klb within the CNS. These data from two independent mouse lines provide convincing evidence that FGF21 signaling within the brain is the mechanism through which protein restriction protects against high-fat diet-induced obesity and glucose intolerance.

To avoid the confounding effects of altered energy density, the LP and HFLP diets were isocaloric to their controls by reciprocally lowering protein and increasing carbohydrate content. Although carbohydrate is known to contribute to FGF21 expression ([@R12]; [@R22]), we feel that it is unlikely that this increase in carbohydrate substantially contributed to the increase in FGF21 in our diets. First, both LP and HFLP robustly upregulate the expression of liver amino acid biosynthetic genes, which are hallmarks of the protein-restricted state. Second, the HFLP diet robustly increases FGF21 despite being low in carbohydrate, having less carbohydrate than our standard control. Therefore, if high carbohydrate were essential, we would not observe effects with the HFLP diet, yet both LP and HFLP robustly increase FGF21 and induce metabolic effects that are dependent on FGF21 and FGF21 signaling in the brain. Similar observations were made in the research by [@R30], in which LP diet increased FGF21, regardless of whether the diet was balanced by fat or carbohydrate. Thus, our data strongly demonstrate that the diets induce a state of protein restriction, leading to increases in FGF21, which acts in the brain to coordinate the metabolic response to protein restriction.

The work described above examines mice whose only choice is to remain on the low-protein diet, and in that context, FGF21 drives a series of metabolic adaptations as well as an increase in total food intake, consistent with the protein-leverage hypothesis ([@R60]). However, animals will adaptively alter food preferences to compensate for reduced protein intake if other protein sources are available ([@R7]; [@R16]; [@R21]; [@R43]; [@R54], [@R55]; [@R60]). We tested whether that change in feeding behavior also requires central FGF21 signaling, first testing the hypothesis that elevated FGF21 would increase protein intake in mice choosing between two isocaloric diets differing in their protein:carbohydrate ratio. Using five individual diets in three different dietary combinations, we demonstrated that ICV FGF21 reliably shifts preference among the diets to increase protein intake without altering total food intake. Analyzing these data as the ratio of cumulative carbohydrate versus protein intake (geometric framework; ([@R50]) indicates that ICV FGF21 increases intake along the protein axis but not along the carbohydrate axis, indicating that FGF21 acts in the brain to specifically increase protein intake without altering carbohydrate or energy intake. It should be noted that for this and other ICV injections, intake was measured over a 24-h window after once-daily FGF21 injections, and thus, it is possible that results include both short-lived effects of FGF21 and later, compensatory changes. A more detailed temporal assessment of intake would be required resolve such possible outcomes.

Although FGF21 increased protein intake in a mixed macronutrient setting, interpretation of the above data is complicated by that fact that the protein:carbohydrate ratio is altered reciprocally in each diet to maintain equal energy density (isocaloric). This issue is particularly relevant because recent studies have suggested that FGF21 acts to reduce sweet taste, consistent with a reduction in carbohydrate intake ([@R56]; [@R62]; [@R65]), implying that the effects on carbohydrate could contribute to the above results.

However, in those prior studies, FGF21 only reduced sweet taste (sucrose, glucose), not carbohydrate (maltodextrin). The diets used in our studies had equal sucrose content but varied in the non-sweet starch maltodextrin. It is, therefore, unlikely that differences in "sweetness" are driving the observations noted above. Nevertheless, we sought to further extend these data by testing FGF21 in a paradigm in which protein (casein) and carbohydrate (maltodextrin) were independently provided as isocaloric liquid solutions. This design offered three advantages. First, the design separates protein from carbohydrate intake, allowing assessment of nutrient consumption in isolation or when paired/contrasted. Second, prior work using a similar paradigm demonstrated that protein-restricted rats increase casein versus maltodextrin intake ([@R43]). Third, the use of the non-sweet carbohydrate maltodextrin avoids confounding effects of sweet taste, although it is acknowledged that mice do exhibit a detectable "taste" for maltodextrin that is independent of sweetness ([@R61]; [@R70]). Using this model, we present compelling evidence that brain FGF21 signaling is required for physiological shifts in macronutrient preference in protein-restricted mice. When the nutrients were provided individually (single-choice), protein-restricted, WT mice increased casein, but not maltodextrin, intake. This observation is important because it suggests that protein restriction does not induce a general state of hyperphagia but, instead, a macronutrient-specific increase in protein intake consistent with the geometric analysis described above. When both nutrients were offered simultaneously (two-choice), protein-restricted WT mice robustly shifted their macronutrient preference toward casein. This shift in preference manifested relatively early (within the first few hours) of exposure, even in mice naive to the solutions. Most important, these effects are completely lost in whole-body *Fgf21*-KO mice as well as in brain-specific Klb-KO mice, strongly suggesting that CNS FGF21 signaling is necessary for the adaptive changes in protein intake. Finally, we demonstrate that ICV injection of FGF21 recapitulates this casein preference in WT, chow-fed mice but not in mice lacking Klb expression in the brain. This latter observation is highly consistent with a very recently published study demonstrating that FGF21 injection selectively increased protein intake relative to carbohydrate or fat intake and that this effect required central Klb ([@R32]). Collectively, these data provide compelling evidence that brain FGF21 signaling mediates a physiologically relevant, adaptive change in macronutrient preference. FGF21 is the only known hormone that drives this response.

The above data provide compelling evidence that FGF21 is essential for mice to alter metabolism and food intake during protein restriction, in both lean and obese (diet-induced obesity \[DIO\]) settings. Considering our previous work ([@R27], [@R29]), the essential contribution of FGF21 has now been demonstrated via three completely independent mouse genetic lines that target different components of the FGF21 axis (GCN2-KO, FGF21KO, and Klb^Camk2a^). This redundancy strongly argues against a potential non-specific effect of any single mouse line. For instance, Klb also mediates the effects FGF15/19, which might contribute to results of the Klb^Camk2a^ model but not the FGF21-KO model. The evidence that FGF21 primarily acts via the brain also begs the question as to the site of FGF21 action. The Camk2a-Cre model has been shown to primarily, but not exclusively, target glutamatergic neurons in the forebrain ([@R5]; [@R6]; [@R10]), and thus, it seems very likely that FGF21 is acting within the forebrain to promote the observed changes in metabolism and food intake during protein restriction. However, the precise site of action remains uncertain, and to date, most work has emphasized FGF21 signaling, either within the hypothalamic suprachiasmatic nucleus (SCN) or paraventricular nucleus (PVN) ([@R5]; [@R35]; [@R40]; [@R46]; [@R52]; [@R65]). This fact explains why Camk2-Cre reduces but does not abolish Klb expression in the brain. The sites of brain FGF21 action remain an area of active research, and it seems unlikely that a single brain area mediates the broad effects on growth, energy expenditure, sympathetic outflow, glucose homeostasis, and food choice. It is now well accepted that hormones, such as leptin, ghrelin, and GLP-1, act within multiple brain areas ([@R2]; [@R23]; [@R39]), and defining the brain areas mediating the broad effects of FGF21 in both pharmacological and physiological (protein-restricted) states will require significant effort moving forward.

The ability to physiologically and behaviorally adapt to a changing nutritional environment is essential for survival. Central FGF21 signaling provides a clear and compelling mechanism to explain the regulatory control of both metabolism and macronutrient preference in response to physiological protein need. Protein restriction induces a distinct array of responses, including a specific appetite for protein, reduced growth, increased energy expenditure, protection against diet-induced obesity and glucose intolerance, and remodeling of white adipose tissue. Liver FGF21 production is robustly increased in that proteinrestricted state, and FGF21 signaling within the brain is absolutely necessary for mice to mount a physiological response to protein restriction. Notably, the nature of this FGF21-dependent response is dependent on the nutritional environment of the animal. If animals have no choice but to continue consuming the lowprotein diet, central FGF21 signaling mediates metabolic adaptations that include increases in total food intake (protein leverage), increases in energy expenditure, reduced growth, and resistance to diet-induced obesity. If the protein-restricted animal has access to alternative protein sources, FGF21 mediates a preference shift, which increases protein intake without increasing total food intake. In other words, the protein-restricted animal will seek and consume protein if it can but will metabolically adapt if necessary, and each of these homeostatic responses depend on FGF21 signaling within the brain. In summary, this liver-to-brain FGF21 signal mechanistically underpins a fundamental aspect of biology and also provides a conceptual framework that cohesively defines the physiological relevance of FGF21.
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CONTACT FOR REAGENT AND RESOURCE SHARING {#S12}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dr. Christopher Morrison (<Christopher.Morrison@pbrc.edu>).

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S13}
--------------------------------------

All procedures involving animals were approved by the PBRC Institutional Animal Care and Use Committee and were performed in accordance with the guidelines and regulations of the NIH Office of Laboratory Animal Welfare. Male mice, 8--12 weeks of age, were used in all experiments and were maintained on chow (Lab Diet 5001) unless transitioned to experimental diets (see below). Mouse models were maintained on the C57BL6 background and were either bred in house or purchased from Jackson Labs. Male *Fgf21*-KO mice on the B6 background were provided by Dr. Steven Kliewer ([@R49]) and bred in the homozygous state with C57BL6 mice (WT; Jackson Labs) used as controls. *Klb*^*lox/lox*^ were provided by Dr. Steven Kliewer ([@R5]; [@R10]), and tissue specific knockouts generated by crossing female *Klb*^*lox/lox*^ mice with male *Klb*^*lox/lox*^ mice also carrying either Adiponectin*-*Cre (adipose-specific) or Camk2a-Cre (brain-specific) ([@R6]). The resulting litters contained Cre positive (knockout) or Cre negative littermate controls, thus maintaining equivalent genetic background. Animals were single housed in 12:12hr light:dark cycle with *ad libitum* access to food or water unless otherwise noted.

METHOD DETAILS {#S14}
--------------

### Experimental Diets {#S15}

Control versus Low Protein (LP) on both low and high-fat backgrounds For all experiments involving dietary manipulation, single housed mice were transferred from chow to the Control diet for approximately 5 days, at which point a random subgroup of animals were transferred to the respective LP diet, HFCON, or HFLP diet. At the end of the study mice were sacrificed during the mid-light cycle in the fed state (unless otherwise noted) using acute exposure to CO~2~ followed by rapid decapitation. Trunk blood was also collected at sacrifice, allowed to clot overnight at 4 ^\[notdef\]^C, centrifuged at 3000×g and serum collected. Tissues were collected and snap frozen in liquid nitrogen for further analysis. Diets were formulated and produced by Research Diets as previously described ([@R19]; [@R27]) and were designed to be isocaloric by equally varying protein and carbohydrate while keeping fat constant. Control diets contained 20% casein (by weight) as the protein source, while the LP diet contained 5% casein. HFCON and HFLP also contained 20% and 5% casein, respectively, but on a background of 60% fat. All diet compositions are provided in [Table S1](#SD1){ref-type="supplementary-material"}.

### Food choice paradigm {#S16}

Mixed macronutrient diets Wild-type C57BL6 mice bearing lateral ventricle cannula were simultaneously offered two isocaloric diets that varied in their protein:carbohydrate ratio ([Table S1](#SD1){ref-type="supplementary-material"}). Mice were offered the choice between 5% versus 35% casein, 10% versus 40% casein, or 5% versus 60% casein. Mice were given one week to adapt to this two-choice paradigm, and then FGF21 (1ug; Eli Lilly and Company, Indianapolis, IN) or saline was injected into the lateral ventricle for 3 consecutive days approximately 3 hours prior to lights off. Food intake was measured daily beginning the day before the injection (Day 0) until after choice normalized.

### Casein versus Maltodextrin Solution Intake {#S17}

Protein versus carbohydrate intake was assessed via a protocol similar to that described by [@R43]. First, mice (wildtype or knockout) were randomly assigned to either 20% casein (Control) or 5% casein (LP) diets for at least one week to establish the protein restricted state. Mice were then offered solutions of casein as a protein source or maltodextrin as a carbohydrate source. Solutions contained 4% nutrient and 0.2% saccharin. For single-choice studies, half the mice in each dietary group were offered casein while the other half offered maltodextrin for 3 consecutive days. For two-choice studies, all mice were simultaneously provided both casein and maltodextrin in their cage. Two-choice studies combined with ICV injection were conducted as above, except that mice had one day of access to the solutions before a single ICV injection of FGF21 (1ug), with liquid consumption measured an additional 2 days.

### Brain cannulation and ICV injections {#S18}

Lateral ventricle guide cannula were surgically implanted in mice anesthetized using isofluorane. The superior and dorsal aspect of the head and neck is shaved and the mouse placed into the stereotaxic device. The skin was prepared by successive scrubbing with nolvasan and alcohol. A 1.5-cm midsagittal skin incision was made to expose the skull. Then a small hole was drilled into the skull using a hand-held dremel tool, and a guide cannula (Plastics One) is targeted to specific brain areas or cerebroventricles based on established stereotaxic coordinates. The cannula is permanently affixed to the skull by means of metal bone screws and quickly drying dental acrylic. A removable obdurator seals the guide cannula when not in use. Analgesics were administered following the procedure and animals recovered at least 1 week to prior to study. On experimental days, animals were subjected to intracerebroventricular administration of either 1 ug FGF21 or saline.

### Glucose tolerance testing {#S19}

Sixteen-hour-fasted mice underwent GTT by i.p. injection with 2g glucose per kg of BW. Blood glucose levels were measured at 0, 15, 30, 45, 60, and 120 min with a glucometer (Accu Check; Roche Diabetes Care, Inc. Indianapolis IN) for GTT. The data for GTT are represented as mg/dL and as area under curve (AUC). Fasted glucose levels are reported at the time of GTT.

### Insulin sensitivity testing {#S20}

Three-hour-fasted mice were injected i.p. with 0.75 IU human insulin (Eli Lilly and Company, Indianapolis, IN) per kg of BW. Blood glucose levels were measured at 0, 15, 30, 60 and 120 min with a glucometer (Accu Check; Roche Diabetes Care, Inc. Indianapolis IN). The data for ITT are presented as a percentage of baseline glucose and as area under curve (AUC).

### Real-time PCR {#S21}

RTPCR for assessment of mRNA levels in liver and adipose tissue (white and brown adipose tissue) RNA extraction and real-time PCR was conducted as described previously ([@R18]; [@R28]). Total RNA was extracted from liver, iWAT, and BAT using TRIzol reagent following the manufacturer's protocol (Invitrogen), with the addition of an RNeasy Lipid Tissue Mini Kit (QIAGEN) for the BAT & iWAT. RNA purity and quantity was determined by spectrophotometry using a NanoDrop (Thermo Scientific). cDNA synthesis was performed with iScript (BioRad) and mRNA was quantified on the ABI 7900 platform using the ABI SYBR Green PCR Master Mix in optical 384-well plates (Applied Biosystems). Primer pairs were designed using the IDT RealTime qPCR Primer Design tool with at least one primer spanning an exon-exon boundary. Target gene expression was normalized with cyclophilin as the endogenous Control.

### Immunoassay determination of FGF21, Insulin, and Adiponectin {#S22}

Concentrations of FGF21 in serum were determined in mice with an ELISA according to the procedure recommended by the manufacturer (no. RD291108200R, Mouse and Rat FGF-21 ELISA, BioVendor). The minimal detectable Concentration of FGF21 with this assay was 18.4 pg/ml. For determination of serum FGF21, 50 ml of serum were diluted in 200 ml of dilution buffer before analysis as previously described ([@R27]). Insulin (\#EZRMI-13K, Rat/Mouse Insulin ELISA, EMD Millipore Corporation) and adiponectin (\#EZMADP-60K/ Mouse Aiponectin EMD Millipore Corporation) was measured with an ELISA according to the procedures per the manufacturer's recommendation.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S23}
---------------------------------------

Data were analyzed using the SAS software package (SAS V9, SAS Institute) using one-way, two-way, or repeated-measures ANOVA using the general linear model procedure. When experiment-wide tests were significant, post hoc comparisons were made using the LSMEANS statement with the PDIFF option, and represent least significant differences tests for pre-planned comparisons. Average daily energy expenditure was analyzed via analysis of covariance (ANCOVA) with body weight as the covariate using the general linear model procedure of SAS. All data are expressed as mean ± SEM, with a probability value of 0.05 considered statistically significant. Groups sizes are described in their respective figure legend.
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![CNS FGF21 Signaling Mediates Low-Protein-Induced Metabolic Responses in Lean Mice\
(A--L) Brain-specific Klb knockout mice (*Klb*^*Camk2a*^) and control littermates (*Klb*^*lox/lox*^) were fed isocaloric control (Con) or low-protein (LP) diet for 7 weeks. (A--I) Circulating FGF21 levels (A), hepatic *Fgf21* mRNA levels (B), *Klb* mRNA levels in various tissues (C), hepatic *Phgdh and Asns* mRNA levels (D), average daily food intake (E), body weight gain over the experiment (F), final body weight gain (G), final fat gain (H), and final lean gain (I) are shown. (J--L) Oxygen consumption (J) and energy expenditure (K) on days 6--8 of diet exposure and *Ucp1* mRNA levels in iWAT and brown adipose tissue (BAT) (L) are depicted.\
Data are represented as means ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001. 8 mice/group.](nihms-1531057-f0002){#F1}

![Protein Restriction Requires FGF21 to Protect against HFD-Induced Obesity and Glucose Intolerance\
(A--L) WT and *Fgf21*-KO mice were fed an HFCon or HFLP diet for 6 weeks. Circulating FGF21 levels (A), body weight (BW) gain in WT mice (B), BW gain in *Fgf21*KO mice (C), final BW change (D), change in body fat (E), body fat percentage (F), average daily food intake (G), *Ucp1* mRNA levels in iWAT (H), glucose tolerance test (GTT) in WT mice (I), and in *Fgf21*-KO mice (J) at 4 weeks on diet, along with GTT area under the curve (K) and insulin levels (L) are shown.\
Data are represented as means ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001. 10 mice/group.](nihms-1531057-f0003){#F2}

![CNS FGF21 Signaling Is Required for Protein Restriction to Protect against Diet-Induced Obesity\
(A--M) Brain-specific Klb knockout mice (*Klb*^*Camk2a*^) and control littermates (*Klb*^*lox/lox*^) were fed either a high-fat control (HFCon) or a high-fat low-protein (HFLP) diet for 10 weeks showing circulating FGF21 levels (A), liver *Fgf21* mRNA levels (B), average of daily food intake (C), *Ucp1* mRNA levels in iWAT and BAT (D), body weight gain over the study (E), final body weight gain (F), fat gain (G), lean gain (H), glucose tolerance test at 6 weeks on diet with area under the curve (AUC) (I), insulin tolerance test (ITT) at 7 weeks on diet with AUC (J), fasted glucose levels at time of GTT (K), insulin levels at week 10 (L), and adiponectin levels at week 10 (M).\
Data are represented as means ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001. 8 mice/group.](nihms-1531057-f0004){#F3}

![FGF21 Acts in the Brain to Increase Protein Intake\
(A--G) Wild-type mice selecting between isocaloric diets containing either 5% or 35% casein were given FGF21 injections into the lateral ventricle for three consecutive days. Shaded area denotes days of injection.\
(A) Intake of 5% casein diet.\
(B) Intake of 35% casein diet.\
(C) Total food intake.\
(D) Preference for 35% casein diet (35% casein intake divided by total).\
(E) Average daily intake of various diets on days 1--5.\
(F) Average preference on days 1--5.\
(G) Average daily protein intake on days 1--5. 8 mice/group; \*p \< 0.05.\
(H--J) Geometric analysis of FGF21-dependent shifts in cumulative protein and carbohydrate intake over days in mice choosing between multiple dietary combinations.\
(H) Geometric analysis of mice choosing between 5% and 35% casein diets.\
(I) Geometric analysis of mice choosing between 10% and 40% casein diets.\
(J) Geometric analysis of mice choosing between 5% and 60% casein diets.\
Horizontal, hashed lines reflect carbohydrate target of the saline group, whereas the vertical, hashed lines reflect protein target of the saline group in black and the FGF21 group in red. Arrows indicate FGF21-induced increase in protein intake. Data are represented as means ± SEM. 7--10 mice/group. \*p \< 0.05.](nihms-1531057-f0005){#F4}

![CNS FGF21 Signaling Is Required for Physiological Shifts in Protein Preference\
(A--H) Wild-type and *Fgf21*-KO mice consumed either control or low-protein (LP) diet for 7 days. Mice were then offered 4% casein or 4% maltodextrin solutions for 3 consecutive days (singlechoice).\
(A) Daily consumption of casein in single choice.\
(B) Daily consumption of maltodextrin in single choice. Mice were then simultaneously offered casein and maltodextrin solutions for 3 consecutive days (two-choice).\
(C) Average maltodextrin, casein, and total liquid intake across the 3 days of two-choice presentation in wild-type mice.\
(D) Average maltodextrin, casein, and total liquid intake across the 3 days of two-choice presentation in *Fgf21*-KO mice.\
(E) Preference for casein over that same 3 day period. Mice with brain-specific Klb deletion (*Klb*^*Camk2a*^) or littermate controls were placed on control of LP for 7 days and then simultaneously offered casein or maltodextrin solutions for 3 consecutive days (two-choice).\
(F and G) Average maltodextrin, casein, and total liquid intake in Klb^lox/lox^ (F) and Klb^Camk2a^ (G) mice across the 3 days of two-choice presentation.\
(H) Preference for casein over that same 3 day period.\
Data are represented as means ± SEM. \*p \< 0.05. 10 mice/diet/genotype](nihms-1531057-f0006){#F5}

![Rapid Appearance of the FGF21-Dependent Protein Preference\
(A--D) Wild-type and *Fgf21*-KO mice consumed either control or low protein (LP) diet for 7 days and were then offered 4% casein solution or 4% maltodextrin for 42 h with continuous measurement of fluid intake.\
(A) Casein intake.\
(B) Maltodextrin intake.\
(C) Total intake.\
(D) Preference for casein. 5 mice/diet/genotype \*p \< 0.05.\
Dark line indicates the means and shaded area the SEM. Fluid consumption during just the first 300 min of exposure is presented in the final column from a subgroup (3/group) of mice provided solutions at identical times.](nihms-1531057-f0007){#F6}

![CNS FGF21 Signaling Increases Protein Intake in Chow Fed Mice\
(A--D) Wild-type mice on chow diet were offered casein and maltodextrin solutions (two-choice) for 24h and were then given a single ICV FGF21 injection, and liquid intake was monitored for 2 additional days. Grey shading denotes 24-h period after ICV injection.\
(A) Casein intake.\
(B) Maltodextrin intake.\
(C) Total liquid intake.\
(D) Preference for casein. Data are represented as means ± SEM. \*p \< 0.05; four mice/group.\
(E--H) Brain-specific Klb knockouts (*Klb*^*Camk2a*^) and control littermates on chow diet were offered casein and maltodextrin solutions for 24 h and then received a single ICV FGF21 injection as above, and liquid consumption was measured over 2 days.\
(E) Casein intake.\
(F) Maltodextrin intake.\
(G) Total liquid intake.\
(H) Preference for casein.\
Data are represented as means ± SEM. \*p \< 0.05. 7--8 mice/group](nihms-1531057-f0008){#F7}

###### 

KEY RESOURCES TABLE

  --------------------------------------------------------------------------------------------------------------------
  REAGENT or RESOURCE                                     SOURCE                                    IDENTIFIER
  ------------------------------------------------------- ----------------------------------------- ------------------
  Chemicals, Peptides, and Recombinant Proteins                                                     

  Human FGF21                                             Eli Lilly and Company, Indianapolis, IN   N/A

  Critical Commercial Assays                                                                        

  FGF21 ELISA                                             Biovendor                                 RD291108200R

  Insulin ELISA                                           EMD Millipore                             EZRMI-13K

  Adiponectin ELISA                                       EMD Millipore                             EZMADP-60K

  Experimental Models: Organisms/Strains                                                            

  Mouse:FGF21-KO                                          Dr. Steven Kliewer                        [@R49]

  Mouse: Camk2a-Cre                                       Dr. Steven Kliewer                        [@R6];\
                                                                                                    [@R5]

  Mouse: Adiponectin-Cre: B6.FVB-Tg(Adipoq-cre)1 Evdr/J   The Jackson Laboratory                    Stock No: 028020

  Mouse: Klb^lox/lox^ (Klb^tm1^)                          Dr. Steven Kliewer                        MGI:5446168\
                                                                                                    [@R10]

  Oligonucleotides                                                                                  

  *Fgf21* Forward: CAAATCCTGGGTGTCAAAGC;                  Integrated DNA Technologies (IDT)         N/A

  *Fgf21* Reverse: CATGGGCTTCAGACTGGTAC                   IDT                                       N/A

  *Klb* Forward: CAGGGATATCTACATCACAGCC                   IDT                                       N/A

  *Klb* Reverse: GTAGCCTTTGATTTTGACCTTGTC                 IDT                                       N/A

  *Fas* Forward: GGGATCTGGTGAAAGCTGTAG                    IDT                                       N/A

  *Fas* Reverse: GTGTTCTCGTTCCAGGATCTG                    IDT                                       N/A

  *Scd-1* Forward: CTGTACGGGATCATACTGGTTC;                IDT                                       N/A

  *Scd-1* Reverse: CGTGCCTTGTAAGTTCTGTG                   IDT                                       N/A

  *Srebp1* Forward: AGATTGTGGAGCTCAAAGACC                 IDT                                       N/A

  *Srebp1* Reverse: CACl 1CGTAGGGTCAGG1 1C                IDT                                       N/A

  *Ucp1* Forward: CACCTTCCCGCTGGACAC                      IDT                                       N/A

  *Ucp1* Reverse: CCCTAGGACACCTTTATACCTAATGG              IDT                                       N/A
  --------------------------------------------------------------------------------------------------------------------

###### Highlights

-   Mice adaptively alter metabolism and food choice during protein restriction

-   The liver hormone FGF21 is robustly increased by protein restriction

-   Metabolic responses to protein restriction require FGF21 signaling in the brain

-   Brain FGF21 also mediates adaptive changes in macronutrient selection
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